Clinical Trial Update: A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years [Phase 3]

View source ↗

Summary

Phase 3 trial to evaluate immunogenicity and safety of MG1111 (BARYCELA Inj.) given as two doses in healthy children aged 12 months to 12 years for Varicella; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicella

Drugs mentioned

• BARYCELA Inj. (MG1111)

Snippet

Sponsor: GC Biopharma Corp | Conditions: Varicella (Chickenpox), Chickenpox Vaccine | Phase 3 | Status: RECRUITING